Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: Rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker

Malaria Journal

Volumn 2, Issue , 2003, Pages 1-7

  Schwöbel, Babett ^a   Alifrangis, Michael ^b   Salanti, Ali ^b   Jelinek, Tomas ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Institute of Tropical Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CYCLOGUANIL; PRIMER DNA; SERINE; TYROSINE; UBIQUINOL CYTOCHROME C REDUCTASE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC STRAIN; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MALE; MUTATIONAL ANALYSIS; NONHUMAN; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT FAILURE; WILD TYPE;

EID: 3042686652     PISSN: 14752875     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2875-2-1     Document Type: Article

References (21)

1. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB and Canfield CJ Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996, 54:62-66
2. Radloff PD, Philipps J, Nkeyi M, Hutchinson D and Kremsner PG Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996, 347:1511-1514
3. Mulenga M, Sukwa TY, Canfield CJ and Hutchinson DB Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther 1999, 21:841-852
4. Anabwani G, Canfield CJ and Hutchinson DB Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J 1999, 18:456-461
5. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ and Hutchinson DB Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999, 60:526-532
6. Bustos DG, Canfield CJ, Canete-Miguel E and Hutchinson DB Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999, 179:1587-1590
7. Llanos-Cuentas A, Campos P, Clendenes M, Canfield CJ and Hutchinson DB Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru. Braz J Infect Dis 2001, 5:67-72
8. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC and Pasvol G Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 2002, 1:1
9. Fry M and Pudney M Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992, 43:1545-1553
10. Srivastava IK, Rottenberg H and Vaidya AB Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 1997, 272:3961-3966
11. Vaidya AB, Lashgari MS, Pologe LG and Morrisey J Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. Mol Biochem Parasitol 1993, 58:33-42
12. Walker DJ, Wakefield AE, Dohn MN, Miller RF, Baughman RP, Hossler PA, Bartlett MS, Smith JW, Kazanjian P and Meshnick SR Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J Infect Dis 1998, 178:1767-1775
13. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F and Vaidya AB Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999, 33:704-711
14. Syafruddin D, Siregar JE and Marzuki S Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol Biochem Parasitol 1999, 104:185-194
15. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K and Cheng Q Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000, 44:2100-2108
16. Thaithong S and Beale GH Resistance of ten Thai isolates of Plasmodium falciparum to chloroquine and pyrimethamine by in vitro tests. Trans R Soc Trop Med Hyg 1981, 75:271-273
17. Trager W and Jensen JB Human malaria parasites in continuous culture. Science 1976, 193:673-675
18. Fidock DA, Nomura T and Wellems TE Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 1998, 54:1140-1147
19. Srivastava IK and Vaidya AB A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999, 43:1334-1339
20. Peters JM, Chen N, Gatton M, Korsinczky M, Fowler EV, Manzetti S, Saul A and Cheng Q Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum. Antimicrob Agents Chemother 2002, 46:2435-2441
21. Jelinek T, Peyerl-Hoffmann G, Muhlberger N, Wichmann O, Wilhelm M, Schmider N, Grobusch MP, Von Sonnenburg F, Gascon J, Laferl H, Hatz C, Alifrangis M, Burchard G, McWhinney P, Schulze M, Kollaritsch H, Da Cunha S, Beran J, Kern P, Gjorup I and Cuadros J Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe. Malar J 2002, 1:11